Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.
Thanks to everyone for the sensitive posts that will be support to all. It feels like Synairgen has been my baby for the last two years and that probably applies to a lot of the individuals posting here. Doc is right that health and family are the most important things in life and I am lucky to have three young grandchildren to enjoy.
Like many, I was so convinced of the science and the probity of the BoD that I invested far too much as a percentage of my liquid assets and ended up with a relatively high average of about 130p. In hindsight the 30,000 shares I bought in the fund raise contributed to that but I wanted to contribute to enabling a safe treatment to reduce the mayhem we were all suffering and so don't regret that, just upset that SNG001 has not made it to the hospitals and chemists. No doubt greed also came into it or I would have sold a chunk near 200p and this is a very big lesson to have learned rather late in life.
After being in mourning yesterday I spent today with a chainsaw and splitting axe at my sailing club which temporarily took out some of the frustration and sadness and so am now totally knackered with blisters on my hands.
Still holding all and unsure what to do. Will probably wait for RM to give an interview or make a statement.
Best wishes to all the very decent people who have contributed here over the past two years.
Spinnaker
I'll go with Matterhorn and Doc83. To avoid possible argument as to bias, the results should not be released until after the last person to fill in their questionnaire after 90 days of their first dose has done so.
Best to all
Spinnaker
In my experience of commercial property rent reviews (which may or may not be the same), an Independent Expert will prepare his own valuation, doing his own research using whatever information he can glean from publicly or privately available resources and his own experience. He may or may not invite representations and counter-reps from the parties but is not bound or limited by any such representations.
An Arbitrator however is a legal or quasi legal position and he is bound by and limited to the evidence presented in the submissions of the parties. An Arbitrator is not being appointed here, it is an Expert as far as I understand.
Spinnaker
Hi xviolet
I see nobody has replied to your post and interesting link. The board seems to be fairly hyped up awaiting news on P3 not surprisingly.
I have had a quick look at the pre-print findings and must say I am a bit unsure about the meaning and relevance to SNG001 vs Omicron. Also how the method of testing undertaken by this research team compares to the in-vitro testing in respect of Delta and Omicron being undertaken by Synairgen at the moment.
Can any of the scientists here please shine some light on this?
Many thanks
Spinnaker
Great letter D-D-R-R
A large cheer to Massive Ray and Docdaneeka. I think you can tell that we are all going to have a comfortable and expectant Christmas.
Yes, we long term holders will be annoyed that we didn't sell a chunk more than a year ago at over £2 and then buy back sub £1 but we are finally at a tipping point that was first expected after P2, then last Christmas I had hoped P3 would be done and dusted before this winter set in. Still, Covid and we are mostly still here, probably even Nolupus, though he hasn't posted recently and are avidly awaiting potentially life changing results in both healthcare and our finances on successful P3 results.
Happy Christmas to all and good health and cheer for 2022 especially all the staff and directors at Synairgen.
Spinnaker
Well I just saw the email from Primary Bid. I wasn't expecting a fund raise now and certainly not at 14.5p. I tried to buy some more through Primary Bid but the offer has closed.
Oh well, let's see what tomorrow brings. It will be interesting. I doubt there will be any immediate news since if it was good and about to be released then surely they would have RNS'd that before the fund raise.
Best to all
Spinnaker
I'm not sure if this has been posted but I didn't know about it.
https://science.thewire.in/the-sciences/everything-you-need-to-know-molnupiravir-merck-new-anti-covid-drug/
Ivermectin and Favipiravir are being trialled under PRINCIPLE. 7,000 volunteers already. It looks like the MHRA are under orders to have a pill or two ready asap. Trial not due to conclude until next year but given what has happened with Molnupavir I wouldn't be so sure.
Price and convenience seem to be favoured by UK gov, perhaps above safety. Not sure this is fair comment in terms of Ivermectin which seems to have a good safety record of course but efficacy data still awaited.
There does not appear to be any sell off of SNG at the moment, the price remaining amazingly stable. The current interest in treatments should give some more airtime to Synairgen.
Best to all
Spinnaker
I am still here and will definitely be up for a meet in due course.
With the recent SP increases Synairgen has single-handedly revived my portfolio which is otherwise looking rather sad.
I'm very pleased that we have finally got back above the placing price.
I'm desperately sad that our product will not now be contributing to saving lives this year but still hopeful that next year will be a new and transforming chapter.
Best to all.
Spinnaker
To be honest I am so far down the pan with most of the shares mentioned in this thread that the surface still seems a long long way away.
Still holding Synairgen strong though and hoping for great things.
Spinnaker
Good news from Kansas.
I don't know if I am mistaken but I got the impression from Dr Castro that the P2 trial for Synairgen had been 'completed' whereas the other trials had been 'filled'. If the distinction was intended it may well mean that Synairgen is a month or so ahead of other trial drugs. This would certainly be good news and potentially give us a few weeks initially with less competition as you hoped Doc. The big 'if' still remains of course as noted by other valued posters.
Best to all.
Spinnaker
Woodie
One thing for sure is the next variant that becomes the most prevalent will by definition be more easily transmissible than Delta which is 90% plus of current new infections in UK. We just don't know whether it will be more injurious.
Also as far as the UK and other highly vaccinated nations are concerned the next variant of concern may be better able to evade antibodies produced by current vaccinations. I expect that this would allow higher viral loads and therefore assist transmissibility making it more likely that such a variant will become the most prevalent.
All these things point to SNG001 being of major assistance in helping prevent severe disease no matter how the virus mutates. The important aspect is that our treatment will assist the body's natural defence and not specifically target a particular virus or variant .
The sooner we get the results of our P3 trial the sooner our company's product can be brought to the fight.
Up Synairgen!
Spinnaker
Jez, from what I have just read in the New York Times
https://www.nytimes.com/live/2021/08/11/world/covid-delta-variant-vaccine?campaign_id=154&emc=edit_cb_20210811&instance_id=37709&nl=coronavirus-briefing®i_id=169216731&segment_id=66001&te=1&user_id=cc5424f0040cce45b83c504bc701f767#world-health-organization-drugs-virus
all three drugs are existing approved drugs and are being repurposed with the hope they will be helpful for Covid.
Again, WHO are still looking for existing drugs to be repurposed presumably because these are a lot cheaper and quicker to trial than novel drugs that have not yet been approved for any purpose.
Spinnaker
Seaboy
I would like to join everyone who has already complimented you on your long and detailed post. I feel very fortunate to have found it tonight after not having read this board for the past week.
You answered some questions I had been mulling and the content was fascinating. Thank you so much.
Very best wishes to all.
Spinnaker
Naewise
I think Shaun said he sold out at about 335 from memory which was break-even.
He did badly out of this but not so badly that he lost his and his family's shirts. I think he will be a lot less stressed now.
I, on the other hand am feeling increasingly more stressed with a high average of 750ish here and pretty much all of my other holdings in the red. If I had some cash I would probably buy in here to reduce my average in the hope that the legal contractual arguments with the government will be sorted fairly quickly and the company is currently selling huge amounts to various NHS trusts and abroad at decent profit levels. If not then there is not much hope.
Best to all
Spinnaker
Woody, yes I have read the 24 May RNS and it confirms the positive results 'in vitro' against Kent and South African variants and also mentions patient dosing in India is imminent. The 'in vitro' testing of the predominant variant would be a minor thing to organise and obviously not as important as actual trial results. However, from a PR point of view as Matml says it would keep the company in the news and help positivity. I don't want to increase expectation unnecessarily but consider that the more bits of evidence accumulated showing viral agnosticism the more we will get additional doctors and scientists on-side and potential pressure from journalists and others to allow early use.
I am still dumbfounded as to why we have no information from the MAP programme and no read-out from the P2 on 'long Covid'
Spinnaker